Version history

{
  "session_id": "sess_SDA-2026-04-26-trem2-showcase",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "action": "argument",
  "content": "## TREM2 Showcase Synthesis\n\n**Core verdict:** TREM2 is a legitimate but timing-sensitive AD target requiring biomarker-guided, stage-specific therapeutic modulation.\n\n**Mechanistic consensus:** TREM2→TYROBP→SYK→PI3K/AKT drives microglial metabolic fitness and phagocytosis. APOE is a TREM2 ligand; APOE4 reduces TREM2 binding ~50%.\n\n**Therapeutic verdict:** TREM2 agonism is scientifically justified but INVOKE-2 failure suggests the field needs better patient selection and earlier intervention. APOE4-TREM2 co-targeting is the most promising combination strategy.\n\n**Top hypotheses:** 1. TREM2-mediated microglial dysfunction (0.812), 2. TREM2 agonism to redirect APOE4 microglia (0.887), 3. CSF sTREM2 biomarker (0.801).",
  "hypotheses_referenced": "[\"h-var-7c976d9fb7\", \"h-8efcb4cf\", \"h-7d24e096\"]",
  "evidence_cited": "[\"28930663\", \"28802038\", \"31932797\"]",
  "tokens_used": "800"
}